USHIFU, LLC (USHIFU) has appointed Mark Schoenberg to the consulting position of chief medical officer (CMO) of the company. As CMO, Schoenberg will assist the company to complete critical clinical trials with the Sonablate 500 technology in the treatment of patients with prostate cancer. Moreover, he will spearhead a scholarly effort to critically evaluate current clinical experiences with HIFU therapy in collaboration with the Sonablate International HIFU Registry.

Schoenberg has 15 years experience as a clinical investigator. He is an internationally recognized expert in the area of Urologic Oncology who has authored over 100 peer-reviewed publications.

Schoenberg will help USHIFU create educational materials describing the use of HIFU technology and will assist in developing a series of initiatives for the treatment of other malignancies. Schoenberg has an active clinical practice and serves as a Professor of Urology at Johns Hopkins University.

Steve Puckett, USHIFU chief executive officer said, “We are thrilled to announce the addition of Dr. Mark Schoenberg to the USHIFU team as Chief Medical Officer of our company. I’ve had the privilege of working with Dr. Schoenberg on a consulting basis over the past several months and his contributions towards our clinical trial research and academic relationships have been extremely valuable. We look forward to leveraging Dr. Schoenberg’s unique skill set as we continue to build a world class healthcare organization.”